Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Fulvestrant |
| Synonyms | |
| Therapy Description |
Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Fulvestrant | Faslodex | ICI 182,780 | Hormone - Anti-estrogens 29 | Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells and is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA mutant | estrogen-receptor positive breast cancer | no benefit | Fulvestrant | Phase II | Actionable | In a Phase II trial, Falsodex (fulvestrant) treatment resulted in similar progression free survival in ER positive breast cancer patients harboring PIK3CA mutations and those who were PIK3CA wild-type (PMID: 27174596). | 27174596 |
| EML4 - ALK | breast cancer | resistant | Fulvestrant | Preclinical - Cell culture | Actionable | In a preclinical study, breast cancer cells expressing EML4-ALK demonstrated resistance to treatment with Faslodex (fulvestrant) in culture (PMID: 32348852). | 32348852 |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02137837 | Phase III | Everolimus + Fulvestrant Anastrozole + Everolimus + Fulvestrant Fulvestrant | S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer | Terminated | USA | 0 |
| NCT06105632 | Phase III | Fulvestrant Everolimus + Exemestane Fulvestrant + PF-07220060 | A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment | Recruiting | USA | TUR | ISR | GBR | CHE | CAN | BRA | AUS | ARG | 7 |
| NCT05238831 | Phase II | Vemurafenib Vinorelbine Palbociclib Irinotecan Alpelisib Capecitabine Atezolizumab Paclitaxel Entrectinib Cobimetinib Nab-paclitaxel Fulvestrant Carboplatin Olaparib Pertuzumab/trastuzumab/hyaluronidase-zzxf Niraparib Vismodegib Alectinib Letrozole Ado-trastuzumab emtansine Bevacizumab Eribulin Anastrozole | SMMART Adaptive Clinical Treatment (ACT) Trial | Withdrawn | 0 | |
| NCT02219789 | Phase I | Fulvestrant Alisertib | Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery | Completed | USA | 0 |
| NCT01528345 | Phase II | Dovitinib + Fulvestrant Fulvestrant | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | Terminated | USA | POL | NLD | ITA | HUN | FRA | ESP | BRA | BEL | AUT | ARG | 4 |
| NCT02936206 | Phase I | Tamoxifen Fulvestrant | Examination of Breast Cancer Cells of Pre-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant. | Terminated | USA | 0 |
| NCT01437566 | Phase II | Apitolisib Fulvestrant Pictilisib | Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy | Completed | USA | NZL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CAN | BEL | AUS | ARG | 10 |
| NCT02632045 | Phase II | Fulvestrant + Ribociclib Fulvestrant | Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer (MAINTAIN) | Active, not recruiting | USA | 0 |
| NCT01633060 | Phase III | Fulvestrant Buparlisib + Fulvestrant | A Phase III Study of BKM120 With Fulvestrant in Patients With HR+, HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi | Terminated | USA | SWE | POL | NOR | NLD | LBN | ITA | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CAN | BGR | BEL | AUT | ARG | 3 |
| NCT03781063 | Phase II | Lasofoxifene Fulvestrant | Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Active, not recruiting | USA | ISR | CAN | 0 |
| NCT02269670 | Phase II | Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole | Phase II Study of Everolimus Beyond Progression | Terminated | USA | 0 |
| NCT04214288 | Phase II | Camizestrant Fulvestrant | A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2) | Active, not recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | 5 |
| NCT05169567 | Phase III | Fulvestrant Abemaciclib + Fulvestrant | Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH) | Active, not recruiting | USA | TUR | SWE | POL | ITA | ISR | HUN | GRC | FRA | ESP | DNK | CZE | BEL | ARG | 3 |
| NCT03555877 | Phase II | Anastrozole Fulvestrant Fulvestrant + Ribociclib Letrozole Exemestane + Ribociclib Letrozole + Ribociclib Anastrozole + Ribociclib Exemestane | Anti-hormonal Therapie With Ribociclib in HR-positive / HER2- Negative Metastatic Breast Cancer (AMICA) | Completed | DEU | 0 |
| NCT02753686 | Phase I | Tamoxifen Exemestane Fulvestrant Letrozole Anastrozole Everolimus + Exemestane | Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy (Treat ER+ight) | Completed | CAN | 0 |
| NCT03280563 | Phase Ib/II | Atezolizumab + Ipatasertib Atezolizumab + Bevacizumab + Exemestane Atezolizumab + Cobimetinib Atezolizumab + Bevacizumab + Fulvestrant Atezolizumab + Bevacizumab + Tamoxifen Atezolizumab + Fulvestrant + Ipatasertib Fulvestrant Atezolizumab + Fulvestrant | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (MORPHEUS HR+BC) | Completed | USA | ISR | 1 |
| NCT02684032 | Phase I | Letrozole Fulvestrant Gedatolisib + Palbociclib | A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer | Completed | USA | 0 |
| NCT06016738 | Phase III | Fulvestrant Letrozole Anastrozole Palazestrant Exemestane | OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-01) | Recruiting | USA | ROU | POL | NLD | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUS | ARG | 8 |
| NCT05654623 | Phase III | Fulvestrant Vepdegestrant | A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. (VERITAC-2) | Recruiting | USA | TUR | SWE | SVK | POL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | FIN | ESP | DEU | CZE | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 8 |
| NCT05564377 | Phase II | Selumetinib Binimetinib + Fulvestrant Binimetinib + Palbociclib Nilotinib + Paclitaxel Binimetinib + Fluorouracil + Leucovorin + Oxaliplatin Panitumumab + Sotorasib Binimetinib Fulvestrant Olaparib Olaparib + Selumetinib Alpelisib + Olaparib Neratinib Neratinib + Palbociclib Fluorouracil + Leucovorin + Oxaliplatin Ipatasertib + Paclitaxel | Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Recruiting | USA | 1 |
| NCT06179303 | Phase II | Tamoxifen Exemestane Abemaciclib Fulvestrant Letrozole Anastrozole | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | Suspended | USA | 0 |
| NCT03241810 | Phase II | Fulvestrant Fulvestrant + Seribantumab | Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer (SHERBOC) | Terminated | USA | ESP | DEU | CAN | BEL | AUT | 0 |
| NCT01797120 | Phase II | Everolimus + Fulvestrant Fulvestrant | Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI | Completed | USA | 0 |
| NCT01296555 | Phase I | Fulvestrant Taselisib Letrozole | A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer | Terminated | USA | FRA | ESP | CAN | 0 |
| NCT05554354 | Phase II | Binimetinib + Fulvestrant Fulvestrant | Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) | Recruiting | USA | 1 |
| NCT04650581 | Phase III | Fulvestrant Fulvestrant + Ipatasertib | Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER) | Active, not recruiting | NZL | CAN | AUS | 0 |
| NCT03926936 | Phase II | Fulvestrant | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study (FUCHSia) | Completed | NLD | BEL | 0 |
| NCT05963984 | Phase II | Fulvestrant + Samuraciclib Fulvestrant | A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants (SUMIT-BC) | Active, not recruiting | USA | TUR | HUN | ESP | 1 |
| NCT06044623 | Phase III | Exemestane Abemaciclib Palbociclib Ribociclib Letrozole Anastrozole Fulvestrant | Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients (IMPORTANT) | Recruiting | SWE | NOR | ITA | GRC | FIN | ESP | 0 |
| NCT02756364 | Phase II | Fulvestrant + Sapanisertib Fulvestrant | MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy | Completed | USA | ESP | 0 |
| NCT03182634 | Phase II | Fulvestrant Ceralasertib + Olaparib Capivasertib Fulvestrant + Neratinib | The UK Plasma Based Molecular Profiling of Advanced Breast Cancer to Inform Therapeutic CHoices (plasmaMATCH) Trial (plasmaMATCH) | Unknown status | GBR | 0 |
| NCT01560416 | Phase II | Fulvestrant Ganetespib | Fulvestrant With or Without Ganetespib in HR+ Breast Cancer | Active, not recruiting | USA | 0 |
| NCT03355157 | FDA approved | Exemestane + Palbociclib Tamoxifen Paclitaxel Exemestane Capecitabine Palbociclib + Tamoxifen Epirubicin Vinorelbine Fulvestrant + Palbociclib Fulvestrant Letrozole Letrozole + Palbociclib | A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA) | Completed | DEU | 0 |
| NCT02964507 | Phase II | Fulvestrant Fulvestrant + Molibresib | Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer | Terminated | USA | GBR | FRA | ESP | CAN | AUS | 1 |
| NCT05305924 | Phase II | Fulvestrant Abemaciclib + Fulvestrant | Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | Recruiting | USA | 0 |
| NCT06630325 | Phase II | Fulvestrant Olaparib + Pegylated liposomal doxorubicin Abemaciclib + Letrozole Abemaciclib Olaparib Olaparib + Temozolomide Abemaciclib + Tamoxifen Abemaciclib + Gemcitabine Gefitinib Abemaciclib + Pemetrexed Disodium Abemaciclib + Exemestane Osimertinib Carboplatin + Gefitinib + Pemetrexed Disodium Carboplatin + Olaparib + Paclitaxel | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer | Not yet recruiting | USA | 0 |
| NCT02206984 | Phase I | Tamoxifen Anastrozole Fulvestrant | Endocrine Response in Women With Invasive Lobular Breast Cancer | Completed | USA | 0 |
| NCT03584009 | Phase II | Fulvestrant Fulvestrant + Venetoclax | A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy | Terminated | USA | GBR | DEU | CAN | AUS | 0 |
| NCT02374099 | Phase II | Azacitidine Fulvestrant | Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant | Terminated | USA | ITA | FRA | ESP | DEU | BEL | 0 |
| NCT02947685 | Phase III | Fulvestrant Pertuzumab Letrozole Anastrozole Exemestane Palbociclib Trastuzumab | Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (PATINA) | Active, not recruiting | USA | NZL | ITA | FRA | ESP | DEU | AUS | 1 |
| NCT02569801 | Phase II | GDC-0810 Fulvestrant | A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy | Terminated | USA | GBR | ESP | DEU | AUS | 1 |
| NCT01610284 | Phase III | Buparlisib + Fulvestrant Fulvestrant | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor (BELLE-2)r | Completed | USA | SVK | POL | NLD | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
| NCT03147287 | Phase II | Palbociclib Fulvestrant + Palbociclib Avelumab + Fulvestrant + Palbociclib Fulvestrant | Palbociclib After CDK and Endocrine Therapy (PACE) | Active, not recruiting | USA | 0 |
| NCT05384119 | Phase Ib/II | C188-9 + Palbociclib C188-9 + Fulvestrant C188-9 + Ribociclib Fulvestrant | Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer | Completed | USA | 0 |
| NCT01953588 | Phase III | Anastrozole Fulvestrant | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | Active, not recruiting | USA | 1 |
| NCT04975308 | Phase III | Exemestane Abemaciclib + LY3484356 LY3484356 Fulvestrant | A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer (EMBER-3) | Active, not recruiting | USA | TUR | NLD | ITA | GRC | FRA | ESP | DEU | CZE | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT03778931 | Phase III | Letrozole Exemestane Elacestrant Fulvestrant Anastrozole | Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer (EMERALD) | Completed | USA | ITA | ISR | IRL | HUN | GRC | GBR | FRA | ESP | DNK | CAN | BEL | AUT | AUS | ARG | 2 |
| NCT04305496 | Phase III | Capivasertib + Fulvestrant Fulvestrant | Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer (CAPItello-291) | Active, not recruiting | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CAN | BEL | AUS | ARG | 6 |
| NCT06607757 | Phase II | Fulvestrant Capivasertib + Fulvestrant | Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer | Not yet recruiting | DEU | 0 |
| NCT05065411 | Phase III | Fulvestrant Exemestane Abemaciclib + Enobosarm Everolimus + Exemestane | Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (VERU-024) | Terminated | USA | 0 |
| NCT06380751 | Phase III | Ribociclib Fulvestrant Camizestrant + Saruparib Anastrozole Camizestrant + Ribociclib Letrozole Camizestrant + Palbociclib Abemaciclib + Camizestrant Exemestane Abemaciclib Palbociclib | Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01) | Recruiting | USA | TUR | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | AUT | AUS | ARG | 11 |
| NCT02422615 | Phase III | Fulvestrant Fulvestrant + Ribociclib | Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. (MONALEESA-3) | Completed | USA | TUR | SWE | POL | NOR | NLD | LBN | ITA | HUN | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BGR | BEL | AUT | AUS | 9 |
| NCT00921115 | Phase II | Anastrozole Fulvestrant | Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer. | Completed | USA | 0 |
| NCT02476786 | Phase II | Anastrozole Fulvestrant Goserelin Tamoxifen Exemestane | Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | Recruiting | USA | 0 |
| NCT05472792 | Phase II | Toremifene Exemestane Tamoxifen Letrozole Anastrozole Fulvestrant | Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) (CAMERAN) | Recruiting | USA | 0 |
| NCT05191004 | Phase Ib/II | NUV-422 Fulvestrant + NUV-422 Fulvestrant | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Withdrawn | USA | 0 |
| NCT02345772 | Phase I | Fulvestrant Docetaxel + Pertuzumab + Trastuzumab | Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer | Terminated | USA | 0 |
| NCT02540330 | Phase II | Fulvestrant | A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant (007) | Terminated | USA | 0 |
| NCT03809988 | Phase II | Fulvestrant Fulvestrant + Palbociclib Letrozole Letrozole + Palbociclib | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) | Completed | SVN | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT04576455 | Phase II | Fulvestrant Giredestrant | A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer) | Active, not recruiting | USA | TUR | POL | ISR | GBR | DEU | BRA | AUS | ARG | 8 |
| NCT02340221 | Phase III | Fulvestrant + Taselisib Fulvestrant | A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER) | Terminated | USA | TUR | SWE | ROU | POL | NLD | ITA | GRC | FRA | FIN | ESP | DEU | CZE | CAN | BGR | AUT | AUS | 11 |
| NCT02983604 | Phase Ib/II | Exemestane Fulvestrant + GS-5829 Exemestane + GS-5829 Fulvestrant | GS-5829 in Combination With Fulvestrant or Exemestane in Women With Advanced Estrogen Receptor Positive, HER2 Negative-Breast Cancer | Terminated | USA | 0 |
| NCT02260661 | Phase I | Fulvestrant AZD8835 | Phase I, Dose Study to Look at the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours | Completed | USA | GBR | 0 |
| NCT02630693 | Phase II | Palbociclib Fulvestrant Tamoxifen | Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer | Completed | CAN | 0 |
| NCT02955394 | Phase II | Fulvestrant Enzalutamide + Fulvestrant | Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer | Active, not recruiting | USA | 0 |
| NCT02626507 | Phase I | Palbociclib Gedatolisib Goserelin Fulvestrant | Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer | Unknown status | USA | 0 |
| NCT02437318 | Phase III | Alpelisib Fulvestrant | Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. (SOLAR-1) | Completed | USA | SWE | ROU | NLD | LBN | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 10 |
| NCT02366130 | Phase II | Tamoxifen Denosumab + Radium Ra 223 dichloride Fulvestrant | Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast Cancer | Completed | USA | 0 |
| NCT02107703 | Phase III | Abemaciclib + Fulvestrant Fulvestrant | A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer (MONARCH 2) | Active, not recruiting | USA | ROU | POL | ITA | GRC | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUS | 6 |
| NCT05038735 | Phase III | Alpelisib + Fulvestrant Fulvestrant | Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-postitive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. (EPIK-B5) | Recruiting | SVK | ROU | POL | ITA | IRL | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BGR | BEL | 1 |
| NCT05501886 | Phase III | Alpelisib + Fulvestrant Fulvestrant + Gedatolisib + Palbociclib Fulvestrant + Gedatolisib Fulvestrant | Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1) | Recruiting | USA | ROU | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 5 |
CKB BOOST